## Supporting information for:

A Permeability-limited Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctanoic acid (PFOA) in Male Rats
Weixiao Cheng and Carla A. Ng*Department of Civil and Environmental Engineering, University of Pittsburgh,Pittsburgh, Pennsylvania 15261, USA
There are 23 pages, 6 figures and 8 tables included in the supporting information.
Table of Contents
S1. Rat Physiology ..... S1
S2. Protein-related Parameters ..... S2
S2-1. Protein concentration ..... S2
S2-2. Protein binding ..... S3
S2-3. Membrane transporters ..... S4
S3. Derivation of Rate Constants ..... S4
S3-1. Passive diffusion rate constants ..... S5
S3-2. Protein binding and dissociation rate constants ..... S7
S3-3. Active transport rate constants ..... S7
S4. Sensitivity and Uncertainty Analysis ..... S8
S5. PFOA Concentration Profile in Compartments ..... S16
S6. PBPK Model Code ..... S19

## S1 Rat Physiology.

Table S1. Male rat physiological parameters.

|  | Blood | Liver | Kidney | Gut | Muscle | Adipose | Rest of Body |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Fractional Volume (\%BW) | $5.4^{1 \mathrm{a}}$ | $3.66{ }^{2}$ | $0.73{ }^{2}$ | $2.69{ }^{2}$ | $40.43{ }^{2}$ | $7^{2}$ | $40.09^{\text {b }}$ |
| Blood Flow Rate ${ }^{2 \mathrm{c}}$ (\%) | - | 2.4 | 14.1 | 15.1 | 27.8 | 7 | $33.6{ }^{\text {b }}$ |
| Interstitial Fluid (mL/g tissue) | - | $0.049^{3}$ | $0.13{ }^{4}$ | $0.28{ }^{5}$ | $0.054^{6}$ | $0.174^{6}$ | $0.18{ }^{\text {d }}$ |
| Blood Volume ( $\mathrm{mL} / \mathrm{g}$ tissue) | - | $0.21^{2}$ | $0.16^{2}$ | $0.034^{7}$ | $0.04{ }^{2}$ | $0.02{ }^{2}$ | $0.036^{\text {e }}$ |
| Capillary Surface Area ${ }^{8} \mathrm{f}\left(\mathrm{cm}^{2} / \mathrm{g}\right)$ | - | 250 | 350 | 100 | 70 | 70 | 100 |
| Bile Duct Volume ${ }^{3}$ | 0.4\% liver tissue volume |  |  |  |  |  |  |
| Renal Filtrate Volume ${ }^{\text {g }}$ | 0.25 mL |  |  |  |  |  |  |
| Gut Lumen Volume ${ }^{9}$ | 4.5\% BW |  |  |  |  |  |  |
| Glomerular Filtration Rate ${ }^{10}$ | $10.74 \mathrm{~mL} / \mathrm{min} / \mathrm{kg} \mathrm{BW}$ |  |  |  |  |  |  |
| Urine Flow Rate ${ }^{1}$ | $200 \mathrm{~mL} / \mathrm{d} / \mathrm{kg} \mathrm{BW}$ |  |  |  |  |  |  |
| Bile Flow Rate ${ }^{1}$ | $90 \mathrm{~mL} / \mathrm{d} / \mathrm{kg} \mathrm{BW}$ |  |  |  |  |  |  |
| Feces Flow Rate ${ }^{\text {h }}$ | 5.63 mL water per day |  |  |  |  |  |  |

Volume calculations were based on density of $1 \mathrm{~g} / \mathrm{mL}^{2}$.
${ }^{\text {a }}$ Plasma volume is $3.12 \%$ of body weight (BW) ${ }^{1}$.
${ }^{\mathrm{b}}$ Fractional volume and blood flow rate were calculated by subtracting the fraction of other tissues from 1.
${ }^{c}$ Expressed as the percent of cardiac output $\left(\mathrm{Q}_{\mathrm{c}}\right) ; \mathrm{Q}_{\mathrm{c}}=0.235 \times \mathrm{BW}^{0.75} \mathrm{~L} / \mathrm{min}$, where the unit of BW is kg .
${ }^{d}$ Based on data availability, it was assumed to be the weighted average of brain, heart and spleen fluids ${ }^{11}$.
${ }^{\mathrm{e}}$ Calculated on the weighted average of blood volume of the "rest of body" ${ }^{2}$.
${ }^{\mathrm{f}}$ Only the data for liver, kidney and muscle were available, the capillary surface area of other tissues was assumed; in kidney, the surface area of glomerular capillary, through which blood filters into filtrate compartment, is $6890 \mathrm{~mm}^{2} / \mathrm{g}$ kidney ${ }^{12}$. Moreover, the area for exchange between each subcompartment was assumed to be the same as the capillary surface area of each tissue, except for the apical membrane of enterocytes and proximal tubules. The microvilli located on these two apical membranes could increase the corresponding surface area significantly. Taking this into consideration, the surface area of gut lumen would be $4.14 \mathrm{~m}^{2} / \mathrm{kg} \mathrm{BW}^{13}$; and the area of apical membrane of proximal tubule would be increased by a factor of 5 , which was assumed the same as the enlargement factor used in describing area increasing due to the numerous projections formed on intestinal wall ${ }^{13}$.
${ }^{\mathrm{g}}$ To calculate the volume of filtrate compartment, we considered the tubular lumen as a cylinder with length of 5.16 $\mathrm{mm}^{14}$ and diameter of $45 \mu \mathrm{~m}^{15}$, and there are about 30000 nephrons in adult rats ${ }^{16}$, therefore, the volume of the filtrate compartment for an adult rat was estimated to be 0.25 mL .
${ }^{h}$ We assumed the PFOA was associated with the water content of feces, which was estimated to be $45 \%$ of total fecal weight ${ }^{17}$. Additionally, we used an estimate of fecal production for male Sprague-Dawley rats of 6.88 g dry weight per day ${ }^{18}$. Given these data the fecal water content was determined.

## S2 Protein-related Parameters.

## S2-1. Protein concentration.

The in-vitro studies measured uptake kinetics of PFOA into cells in units of $\mathrm{nmol} / \mathrm{mg}$ protein $/ \mathrm{min}$ (normalized to the total protein content in the cells). The total protein content of each tissue (Table S2) was used in our model to convert the in vitro uptake value to a first-order rate constant for transport (in units of s ${ }^{-1}$ ) specific to each type of tissue.

Table S2. Protein concentration in compartments.

|  | $\begin{gathered} \mathrm{C}_{\text {total }}{ }^{19 \mathrm{a}} \\ (\mathrm{mg} / \mathrm{mL}) \end{gathered}$ | $\begin{gathered} \mathrm{C}_{\mathrm{Alb}} \\ (\mu \mathrm{~mol} / \mathrm{L}) \end{gathered}$ | $\begin{gathered} \mathrm{C}_{\text {L-FABP }} \\ (\mu \mathrm{mol} / \mathrm{L}) \end{gathered}$ | $\begin{gathered} \mathrm{C}_{\mathrm{a} 2 \mathrm{u} \text {-globulin }} \\ (\mu \mathrm{mol} / \mathrm{L})^{\mathrm{e}} \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: |
| Plasma | 67 | $486{ }^{16}$ |  |  |
| Liver Fluid |  | $243{ }^{20}$ |  |  |
| Liver Tissue | 40 |  | $133^{21 \mathrm{~d}}$ |  |
| Kidney Fluid |  | $243{ }^{\text {c }}$ |  |  |
| Kidney Tissue | 34 |  | $2.65^{22}$ | $110^{23}$ |
| Gut Fluid |  | $146^{\text {c }}$ |  |  |
| Gut Tissue | 20.6 |  |  |  |
| Muscle Fluid |  | $146^{24}$ |  |  |
| Muscle Tissue | 20.6 |  |  |  |
| Adipose Fluid |  | $73^{24}$ |  |  |
| Adipose Tissue | 20.6 |  |  |  |
| Rest of Body Fluid |  | $73^{\text {c }}$ |  |  |
| Rest of Body Tissue | 20.6 |  |  |  |

${ }^{\text {a }}$ Total protein content of liver, kidney and gut were estimated based on a study that investigated the distribution of heart FABP in different organs; in that study, heart FABP concentrations were normalized to both protein content and organ weight; based on that information the protein content of each tissue could be determined. For other tissues the same protein concentration as that in gut was assumed.
${ }^{\mathrm{b}}$ Calculated assuming molecular weight of albumin is $65 \mathrm{~kg} / \mathrm{mol}^{25}$.
${ }^{c}$ Kidney and gut were assumed to have similar albumin levels as liver and the "rest of body" was the same as muscle.
${ }^{\mathrm{d}}$ Calculated assuming molecular weight of L-FABP is $14 \mathrm{~kg} / \mathrm{mol}^{23}$.
${ }^{\mathrm{e}} \mathrm{a} 2 \mathrm{u}$-globulin is a male-specific protein and its molecular weight is $15.5 \mathrm{~kg} / \mathrm{mol}^{23}$.

## S2-2. Protein binding.

Table S3. Association constants $\left(\mathrm{K}_{\mathrm{a}}\right)$ and binding sites (n) for PFOA binding to proteins and their sources.

|  | $\mathbf{K}_{\mathbf{a}}\left(\mathbf{M}^{-1}\right)$ | $\mathbf{n}$ | Source |
| :---: | :---: | :---: | :---: |
| Albumin | $3.1 \times 10^{3}$ | 7.8 | Han et al. (2003) |
| L-FABP $^{\mathbf{a}}$ | $1.2 \times 10^{5}$ |  |  |
|  | $4.0 \times 10^{4}$ | 3 | Woodcroft et al. (2010) ${ }^{27}$ |
|  | $1.9 \times 10^{4}$ |  |  |
| $\mathbf{a 2 u - g l o b u l i n}$ | $5.0 \times 10^{2}$ | 1 | Han et al. (2004) |

${ }^{\text {a }}$ Based on Woodcroft et al. ${ }^{27}$, three binding sites exist for L-FABP interacting with PFOA, with association constants of $1.2 \times 10^{5}, 4.0 \times 10^{4}$ and $1.9 \times 10^{4} \mathrm{M}^{-1}$.

We used the equilibrium association constant $\left(\mathrm{K}_{\mathrm{a}}\right)$ to derive individual rate constants for protein binding and dissociation ( $\mathrm{b}_{\mathrm{on}}$ and $\mathrm{b}_{\text {off }}$ ) according to the same procedure described in the original fish model ${ }^{6}$. The equations used are listed below:

$$
\begin{align*}
& \mathrm{K}_{\mathrm{a}}=\frac{\mathrm{k}_{\mathrm{on}}^{\mathrm{p}}}{\mathrm{k}_{\mathrm{off}}^{p}}  \tag{S1}\\
& \frac{\mathrm{dc} \mathrm{C}_{\mathrm{unocc}}^{\mathrm{p}}}{\mathrm{dt}}=\mathrm{k}_{\mathrm{off}}^{\mathrm{p}} \mathrm{C}_{\text {bound }}-\mathrm{k}_{\mathrm{on}}^{\mathrm{p}} C_{\mathrm{unocc}}^{\mathrm{p}} C_{\text {free }}  \tag{S2}\\
& \mathrm{b}_{\text {on }}=\mathrm{k}_{\mathrm{on}}^{\mathrm{p}} \mathrm{C}_{\mathrm{unocc}}^{\mathrm{p}}  \tag{S3}\\
& \mathrm{~b}_{\text {off }}=\mathrm{k}_{\mathrm{off}}^{\mathrm{p}} \tag{S4}
\end{align*}
$$

Where:
$\mathrm{k}_{\mathrm{on}}^{\mathrm{p}}$ - association rate constant, $\mathrm{M}^{-1} \mathrm{~s}^{-1}$.
$\mathrm{k}_{\mathrm{off}}^{\mathrm{p}}-$ dissociation rate constant, $\mathrm{s}^{-1}$.
$\mathrm{C}_{\mathrm{unocc}}^{\mathrm{p}}$ - concentration of unoccupied binding sites of protein p .
$\mathrm{C}_{\text {bound }}$ - concentration of PFOA bound to protein.
$\mathrm{C}_{\text {free }}-$ concentration of free PFOA.
$\mathrm{b}_{\mathrm{on}}$ - PFOA binding rate constant, $\mathrm{s}^{-1}$.
$\mathrm{b}_{\text {off }}-$ rate constant for dissociation from protein, $\mathrm{s}^{-1}$.

The initial concentration of unoccupied binding sites is the total concentration of protein in each compartment times the number of binding sites per protein molecule. It has been demonstrated that steady-state solutions depend only on $\mathrm{K}_{\mathrm{a}}$ but not on the individual association and dissociation rate constants $\left(\mathrm{k}_{\text {on }}\right.$ and $\left.\mathrm{k}_{\text {off }}\right)$, which means that we can set a fixed value (e.g. $0.01 \mathrm{~s}^{-1}$ ) for $\mathrm{k}_{\text {off }}$ and use it to calculate $\mathrm{k}_{\text {on }}$ based on the above equations ${ }^{6}$. The parameter $\mathrm{k}_{\text {off }}$ was included in the model sensitivity analysis, assuming it is uniformly distributed from $0.001 \mathrm{~s}^{-1}$ to $0.1 \mathrm{~s}^{-1}$ in order to understand the influence of this parameter on the dynamic solutions in this study.

S2-3. Membrane transporters.

Table S4. Protein-facilitated PFOA uptake velocity for five transporters and their sources.

| Transporters | In vitro net flux (nmol/mg protein/min) | Sources |
| :---: | :---: | :---: |
| Oat1 | 0.34 |  |
| Oat3 | 0.48 | Weaver et al. $(2010)^{29}$ |
| Oatp1a1 | 0.35 |  |
| Ntcp | 0.1 | Zhao et al. $(2015)^{30}$ |
| Ost $\boldsymbol{\alpha} / \boldsymbol{\beta}$ | 0.41 |  |

The method used to extrapolate measured in vitro uptake rates to corresponding absorption and efflux rate constants in our model is explained in Section S3-3.

## S3. Derivation of Rate Constants.

All methods and equations used in this section to derive rate constants were based on the original fish model ${ }^{6}$ except for the active transport rate constant. We modified the original method for deriving the active transport parameters by taking into consideration the fact that the ratio of active uptake to passive diffusion rate is consistent under both in-vitro and in-vivo situations, as described in Section S3-3
below.

## S3-1. Passive diffusion rate constants.

Before calculating the passive diffusion rate, the effective permeability for each tissue must be estimated. Based on the original fish model, a single cell with average surface area (A) of $4000 \mu \mathrm{~m}^{2}$ was assumed to calculate permeability ${ }^{6}$.

Table S5. Effective permeability ( $\mathrm{P}_{\text {eff }}$ ) for each tissue and steady-state cell-water concentration ratios $\left(\mathrm{CR}_{\mathrm{ss}}^{\mathrm{c}-\mathrm{w}}\right)$.

| Tissue | Blood | Liver | Kidney | Gut | Muscle | Adipose | Rest of Body |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\mathbf{P}_{\text {eff }}(\mathbf{m} / \mathbf{s})$ | $4.98 \mathrm{e}-08$ | $5.15 \mathrm{e}-08$ | $4.38 \mathrm{e}-08$ | $2.65 \mathrm{e}-08$ | $2.65 \mathrm{e}-08$ | $2.65 \mathrm{e}-08$ | $2.65 \mathrm{e}-08$ |
| $\mathbf{C R}_{\text {ss }}^{\text {c-w }}$ |  |  |  |  |  |  |  |
| Hepatocyte to bile |  |  | 7.28 |  |  |  |  |
| Kidney to filtrate |  |  | 6.19 |  |  |  |  |
| Enterocyte to gut lumen |  |  | 3.75 |  |  |  |  |

According to Fick's Law, permeability is expressed as:

$$
\begin{equation*}
P_{\text {eff }}=\frac{\mathrm{J}}{\mathrm{~A} \Delta \mathrm{C}} \tag{S5}
\end{equation*}
$$

J is the initial passive diffusion flux extracted from Weaver et al. ${ }^{29}$ and it has an average value of $0.13 \mathrm{nmol} / \mathrm{mg}$ protein $/ \mathrm{min}$, which is converted to $\mathrm{mol} / \mathrm{s}$ by scaling to tissue-specific protein content of each cell. $\Delta \mathrm{C}$ is the concentration of PFOA in the exposure medium, which in Weaver et al. study was $10 \mu \mathrm{~mol} / \mathrm{L}$.

Once $\mathrm{P}_{\text {eff }}$ was determined, we calculated the passive diffusion rate as described below.

For diffusion between blood (B) and the interstitial fluid compartment in each tissue $(i \mathrm{~F})$, the overall mass transfer coefficients are:

$$
\begin{equation*}
\mathrm{k}^{\mathrm{iF}-\mathrm{B}}=\mathrm{k}^{\mathrm{B}-\mathrm{iF}}=\left(\frac{1}{\mathrm{Q}_{\mathrm{B}}^{\mathrm{i}}}+\frac{1}{\mathrm{P}_{\mathrm{eff}}^{\mathrm{B}} \mathrm{~A}^{\mathrm{B}-\mathrm{iF}}}\right)^{-1} \tag{S6}
\end{equation*}
$$

$Q_{B}^{i}$ is the blood flow to each tissue, and $A^{B-i F}$ is the exchange area between blood and fluid compartment (Table S1). Then the passive diffusion rate constants can be
determined as:

$$
\begin{align*}
& b^{i F-B}=\frac{k^{i F-B}}{v^{i F}}  \tag{S7}\\
& b^{B-i F}=\frac{k^{B-i F}}{v^{B}} \tag{S8}
\end{align*}
$$

$V^{B}$ and $V^{i F}$ are the volume of blood and fluid compartment, respectively (Table S1). For transport between the fluid (iF) and tissue (iT) subcompartment in each tissue, only permeability accounts for the overall mass transfer coefficients for passive diffusion:

$$
\begin{equation*}
k^{i F-i T}=k^{i T-i F}=P_{e f f}^{i} f^{i F-i T} \tag{S9}
\end{equation*}
$$

The passive diffusion rate constants are:

$$
\begin{align*}
& b^{i F-i T}=\frac{k^{i F-i T}}{v^{i F}}  \tag{S10}\\
& b^{i T-i F}=\frac{k^{i T-i F}}{v^{i T}} \tag{S11}
\end{align*}
$$

For tissues containing other subcompartments (iO), namely, filtrate, bile, or gut lumen, the overall mass transfer coefficients are:

$$
\begin{align*}
& k^{i 0-i T}=P_{e f f}^{i} A^{i T-i O}  \tag{S12}\\
& k^{i T-i O}=\frac{k^{i O-i T}}{C R_{S S}^{C-W}} \tag{S13}
\end{align*}
$$

$\mathrm{CR}_{\mathrm{SS}}^{\mathrm{C}-\mathrm{W}}$ is the steady-state cell-water concentration ratio, which was estimated using the data of Weaver et al ${ }^{29}$. The steady-state concentration in the cells was determined by extrapolating their concentration to very long times ( $>10^{6} \mathrm{~min}$ ) and the concentration in the medium was assumed to be constant $(10 \mu \mathrm{~mol} / \mathrm{L})^{6}$.

The passive diffusion rate constants for these tissues are:

$$
\begin{align*}
& b^{i \mathrm{i}-\mathrm{iO}}=\frac{\mathrm{k}^{\mathrm{i} T-\mathrm{iO}}}{\mathrm{v}^{\mathrm{iT}}}  \tag{S14}\\
& \mathrm{~b}^{\mathrm{iO-iT}}=\frac{\mathrm{k}^{\mathrm{iO-iT}}}{\mathrm{v}^{\mathrm{iO}}} \tag{S15}
\end{align*}
$$

S3-2. Protein binding and dissociation rate constants.

See Section S2-2.

## S3-3. Active transport rate constants.

Table S6. In vitro-in vivo extrapolation of transporter-mediated uptake and efflux rate constants (b) of PFOA.

| Transporters | In vivo transport rate constants $\mathbf{b}\left(\mathbf{s}^{-1}\right)^{\mathrm{a}}$ <br> Kidney | Liver |
| :---: | :---: | :---: |

[^0]To keep consistent ratios of active transport and passive diffusion before and after derivation from in-vitro studies, we used the similar method as deriving passive diffusion rate constants to estimate the active transport rate constants. Instead of using the flux measured in empty vector-transfected cells, the net flux (Table S4), which is the difference between the flux of transporter-expressing cell and the empty vectortransfected cell, was applied to obtain the active transport coefficient based on Equation (S5). Active transport rate constants can be determined from the transport coefficient multiplied by the surface area for exchange and then divided by the corresponding compartment volume.

In kidney tissue, Oat1 and Oat3, located at the basolateral membrane of proximal tubules are responsible for the clearance of PFOA from kidney to urine $\left(\mathrm{b}_{\text {clear }}\right)^{31}$ :

$$
\begin{equation*}
b_{\text {clear }}=b_{\text {oat1 }}^{K}+b_{\text {oat3 }}^{K} \tag{S16}
\end{equation*}
$$

While Oatp1al, located on the apical membrane drives reabsorption of PFOA from urine back to systemic circulation $\left(\mathrm{b}_{\text {reab }}\right)^{31}$ :

$$
\begin{equation*}
\mathrm{b}_{\text {reab }}=\mathrm{b}_{\text {oatp1a1 }}^{\mathrm{K}} \tag{S17}
\end{equation*}
$$

Another transporter, Ost $\alpha / \beta$, was also considered for the male rat, which may account for some of the observed gender differences ${ }^{32}$. Ost $\alpha / \beta$ is located on the basolateral membrane and could excrete PFOA out of proximal tubules ${ }^{31}$. The efflux rate constant ( $\mathrm{b}_{\text {efflux }}$ ) is:

$$
\begin{equation*}
\mathrm{b}_{\mathrm{efflux}}=\mathrm{b}_{\mathrm{ost} \alpha / \beta}^{\mathrm{K}} \tag{S18}
\end{equation*}
$$

In liver tissue, two basolateral membrane transporters, Ntcp and Oatp1a1 could facilitate the PFOA uptake process ${ }^{30}$, and the absorption rate constant $\left(b_{\text {abs }}\right)$ is:

$$
\begin{equation*}
\mathrm{b}_{\mathrm{abs}}=\mathrm{b}_{\text {oatp } 1 \mathrm{a} 1}^{\mathrm{L}}+\mathrm{b}_{\mathrm{Ntcp}}^{\mathrm{L}} \tag{S19}
\end{equation*}
$$

Unlike passive diffusion, all active transport processes are assumed to be unidirectional in our model.

## S4 Sensitivity and Uncertainty Analysis.

Our model contains a total of 74 parameters for predicting the distribution of PFOA in rats. Scaling functions were used to estimate the physiological parameters such as tissue volume and blood flow rate. The volume fraction of "rest of body" and the blood flow to "rest of body" were calculated by subtracting the fraction of other tissues from 1. Given this reparameterization, 72 independent parameters were included in the model. To conduct uncertainty and sensitivity analysis, all parameters were sampled from uniform, normal or log-normal distributions. Body weight and dose were assumed to be normally distributed, and their means were estimated as the
average values from corresponding experimental studies with a coefficient of variation (CV) of 0.15 , estimated based on Kemper's study ${ }^{33}$, where the data of body weight of individual rat and actual dose used in each experiment were available. Another parameter related to protein binding, the dissociation rate constant, $\mathrm{k}_{\text {off }}$, was sampled from a uniform distribution ranging from $0.001 \mathrm{~s}^{-1}$ to $0.1 \mathrm{~s}^{-1}$, since no studies currently exist to measure this parameter. All other parameters were assumed to be log-normally distributed, with the values collected from the literature used as the geometric means ( $\mathrm{e}^{\mu}$, where $\mu$ is the mean of the corresponding normal distribution) for each parameter; and the geometric standard deviation ( $\mathrm{e}^{\sigma}$, where $\sigma$ is the standard deviation of the corresponding normal distribution) were assumed based on confidence factors (Cf). The Cf is an intuitive measure of variance in log-normal distributions ${ }^{34}$. For example, a Cf of 2 indicates that $95 \%$ of the values lie between $1 / 2$ and 2 times the median. According to the assumed Cf of each input parameter (Table S7), $\sigma$ can be determined as ${ }^{34}$ :

$$
\begin{equation*}
\sigma=\frac{1}{2} \operatorname{lnCf} \tag{S20}
\end{equation*}
$$

Table S7 summarizes the geometric mean and assumed Cf for each parameter as well as the argument to estimate those parameters. For Cf , a value of 3 indicate fairly high uncertainty as it assumes a range of about one order of magnitude. We therefore chose a Cf of 3 when few or no data were available for estimation of uncertainty or variability.

The sensitivity of the model to each parameter was estimated based on correlation analysis, as shown in Figures S1-S3.

Table S7. Assumed confidence factors (Cf) for input parameters in the model.

| Parameter | Value | $\begin{aligned} & \text { Assumed } \\ & \quad \text { Cf } \end{aligned}$ | Arguments to estimate each Cf |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Range |  | Notes |
|  |  |  | Lower | Upper |  |
| Rat physiology |  |  |  |  |  |
| Blood volume (VB) | 5.4 \%BW | 1.7 |  |  | The range of kidney, liver, gut, muscle, and adipose volume were obtained from Brown et al. ${ }^{2}$. Their corresponding Cf values were calculated based on the $2.5^{\text {th }}$ and $97.5^{\text {th }}$ percentile, which were assumed to be the lower and upper bound, respectively. For other tissue volume parameters, we assumed the Cfs were the same as the largest Cf value of adipose volume. The range of adipose is based on mouse data. |
| Plasma volume (Vplasma) | 3.12 \%BW | 1.7 | - | - |  |
| Kidney volume (VK) | 0.73 \%BW | 1.4 | 0.49 | 0.91 |  |
| Liver volume (VL) | 3.66 \%BW | 1.6 | 2.14 | 5.16 |  |
| Gut volume (VG) | 2.69 \%BW | 1.4 | 2 | 4 |  |
| Muscle volume (VM) | 40.43 \%BW | 1.1 | 35.36 | 45.5 |  |
| Adipose volume (VA) | 7 \%BW | 1.7 | 5 | 14 |  |
| Filtrate volume (VFil) | 0.25 mL | 1.7 | - | - |  |
| Bile duct volume (Vbile) | 0.4 \% liver tissue | 1.7 | - | - |  |
| Gut lumen volume (VGL) | 4.5 \%BW | 1.7 | - | - |  |
| Kidney blood volume (VKB) | $0.16 \mathrm{~mL} / \mathrm{g}$ tissue | 1.6 | 0.11 | 0.27 |  |
| Liver blood volume (VLB) | $0.21 \mathrm{~mL} / \mathrm{g}$ tissue | 1.5 | 0.12 | 0.27 | The range of kidney, liver and muscle blood volume were obtained from Brown et al. ${ }^{2}$. For gut, muscle, adipose, and "rest of body" blood volume and liver and muscle interstitial volume, the same assumptions as above were made to estimate their Cf values. While for kidney, gut, adipose, and the "rest of body" interstitial volume, since their values are relatively large, we assumed their Cfs to be either 1.5 or 1.6 given that these fractional values must be less than $1 \mathrm{~mL} / \mathrm{g}$ tissue. |
| Gut blood volume (VGB) | $0.034 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | - | - |  |
| Muscle blood volume (VMB) | $0.04 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | 0.01 | 0.09 |  |
| Adipose blood volume (VAB) | $0.02 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | - | - |  |
| Rest of body blood volume (VRB) | $0.036 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | - | - |  |
| Kidney interstitial fluid volume (VKF) | $0.13 \mathrm{~mL} / \mathrm{g}$ tissue | 1.6 | - | - |  |
| Liver interstitial fluid volume (VLF) | $0.049 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | - | - |  |
| Gut interstitial fluid volume (VGF) | $0.28 \mathrm{~mL} / \mathrm{g}$ tissue | 1.5 | - | - |  |
| Muscle interstitial fluid volume (VMF) | $0.054 \mathrm{~mL} / \mathrm{g}$ tissue | 3 | - | - |  |
| Adipose interstitial fluid volume (VAF) | $0.174 \mathrm{~mL} / \mathrm{g}$ tissue | 1.6 | - | - |  |
| Rest of body interstitial fluid volume (VRF) | $0.18 \mathrm{~mL} / \mathrm{g}$ tissue | 1.6 | - | - |  |


| Parameters | Values | $\begin{aligned} & \text { Assumed } \\ & \mathbf{C f} \end{aligned}$ | Arguments to estimate each Cf |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Range |  | Notes |
|  |  |  | Lower | Upper |  |
| Blood flow to kidney (QBK) | 14.1 \% Cardiac Output | 1.4 | 9.5 | 19 | The range of blood flow to kidney, liver and gut came from Brown et al. ${ }^{2}$. For QGFR, Qurine, Qbile, and Qfeces, we assumed their Cfs to be the same as the largest Cf value of QBL . While for QBM and QBA, as their values are constrained to be less than 1 , we assumed their Cfs were 1.3. |
| Blood flow to liver (QBL) | 2.4 \% Cardiac Output | 2.7 | 0.8 | 5.8 |  |
| Blood flow to gut (QBG) | 15.1 \% Cardiac Output | 1.3 | 11.1 | 17.8 |  |
| Blood flow to muscle (QBM) | 27.8 \% Cardiac Output | 1.3 | - | - |  |
| Blood flow to adipose (QBA) | 7 \% Cardiac Output | 1.3 | - | - |  |
| Glomerular filtration rate (QGFR) | $10.74 \mathrm{~mL} / \mathrm{min} / \mathrm{kg} \mathrm{BW}$ | 2.7 | - | - |  |
| Urine flow rate (Qurine) | $200 \mathrm{~mL} / \mathrm{d} / \mathrm{kg} \mathrm{BW}$ | 2.7 | - | - |  |
| Bile flow rate (Qbile) | $90 \mathrm{~mL} / \mathrm{d} / \mathrm{kg} \mathrm{BW}$ | 2.7 | - | - |  |
| Feces flow rate (Qfeces) | 5.63 mL water/day | 2.7 | - | - |  |
| Protein binding |  |  |  |  |  |
| Albumin concentration in blood ( $\mathrm{C}_{\text {AlbB }}$ ) | $486 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - | No data on the range of protein content in tissues were available. We assume Cf values of 3 for all protein concentration parameters. |
| Albumin concentration in kidney fluid ( $\mathrm{C}_{\text {AlbKF }}$ ) | $243 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Albumin concentration in liver fluid ( $\mathrm{C}_{\text {AlbLF }}$ ) | $243 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Albumin concentration in gut fluid ( $\mathrm{C}_{\text {AlbGF }}$ ) | $146 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Albumin concentration in muscle fluid ( $\mathrm{C}_{\text {AlbMF }}$ ) | $146 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Albumin concentration in adipose fluid ( $\mathrm{C}_{\mathrm{AlbAF}}$ ) | $73 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Albumin concentration in rest of body fluid ( $\mathrm{C}_{\text {AlbrF }}$ ) | $73 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| L-FABP concentration in kidney tissue ( $\mathrm{C}_{\text {LFABPKT }}$ ) | $2.65 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| L-FABP concentration in liver tissue ( $\mathrm{C}_{\text {LFABPLT }}$ ) | $133 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| a2u-globulin concentration in kidney tissue ( $\mathrm{C}_{\mathrm{a} 2 \mathrm{uKT}}$ ) | $110 \mu \mathrm{~mol} / \mathrm{L}$ | 3 | - | - |  |
| Association constant of albumin ( $\mathrm{K}_{\mathrm{a}}$ ) | $3.1 \times 10^{3} \mathrm{M}^{-1}$ | 3.5 | $2.6 \times 10^{3}$ | $3.12 \times 10^{4}$ | The range for $K_{a}$ was estimated based on data from human serum albumin ${ }^{35}$. |
| Association constant of L-FABP binding site $1\left(\mathrm{~K}_{\text {LFABPI }}\right)$ | $1.2 \times 10^{5} \mathrm{M}^{-1}$ | 3.5 | - | - |  |
| Association constant of L-FABP binding site 2 ( $\mathrm{K}_{\text {LFABP2 }}$ ) | $4.0 \times 10^{4} \mathrm{M}^{-1}$ | 3.5 | - | - |  |
| Association constant of L-FABP binding site 3 ( $\mathrm{K}_{\text {LFABP3 }}$ ) | $1.9 \times 10^{4} \mathrm{M}^{-1}$ | 3.5 | - | - |  |
| Association constant of a 2 u -globulin ( $\mathrm{K}_{\mathrm{a} 2 \mathrm{u}}$ ) | $5.0 \times 10^{2} \mathrm{M}^{-1}$ | 3.5 | - | - |  |


| Parameters | Values | $\underset{\text { Cf }}{\text { Assumed }}$ | Arguments to estimate each Cf |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | Notes |
|  |  |  | Lower | Upper |  |
| Passive diffusion and Active transport |  |  |  |  |  |
| Capillary surface area of kidney (AK) | $350 \mathrm{~cm}^{2} / \mathrm{g}$ tissue | 3 | - | - | No data were available on the range of surface area parameters. We assume Cf values of 3 for all of them. |
| Glomerular capillary surface area in kidney (AKG) | $6890 \mathrm{~mm}^{2} / \mathrm{g}$ tissue | 3 | - | - |  |
| Enlargement factor of apical membrane of proximal tubule (n) | 5 | 3 | - | - |  |
| Capillary surface area of liver (AL) | $250 \mathrm{~cm}^{2} / \mathrm{g}$ tissue | 3 | - | - |  |
| Capillary surface area of gut (AG) | $100 \mathrm{~cm} 2 / \mathrm{g}$ tissue | 3 | - | - |  |
| Capillary surface area of gut lumen (AGL) | $4.14 \mathrm{~m}^{2} / \mathrm{kg} \mathrm{BW}$ | 3 | - | - |  |
| Capillary surface area of muscle(AM) | $70 \mathrm{~cm}^{2} / \mathrm{g}$ tissue | 3 | - | - |  |
| Capillary surface area of adipose (AA) | $70 \mathrm{~cm}^{2} / \mathrm{g}$ tissue | 3 | - | - |  |
| Capillary surface area of rest of body (AR) | $100 \mathrm{~cm}^{2} / \mathrm{g}$ tissue | 3 | - | - |  |
| Effective permeability for blood ( $\mathrm{P}_{\text {effB }}$ ) | $4.98 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - | The Cf values for permeability and active transport parameters were assumed to be the same as the value used in the Yang. et al. ${ }^{36}$ study. |
| Effective permeability for kidney ( $\mathrm{P}_{\text {effk }}$ ) | $4.38 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Effective permeability for liver ( $\mathrm{P}_{\text {effl }}$ ) | $5.15 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Effective permeability for gut ( $\mathrm{P}_{\text {effG }}$ ) | $2.65 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Effective permeability for muscle ( $\mathrm{P}_{\mathrm{effm}}$ ) | $2.65 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Effective permeability for adipose ( $\mathrm{P}_{\text {effA }}$ ) | $2.65 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Effective permeability for rest of body ( $\mathrm{P}_{\text {effr }}$ ) | $2.65 \times 10^{-8} \mathrm{~m} / \mathrm{s}$ | 5 | - | - |  |
| Steady-state cell-water concentration ratio for kidney ( $\left.\mathrm{CR}_{\text {ss }} \mathrm{K}\right)$ | 6.19 | 5 | - | - |  |
| Steady-state cell-water concentration ratio for liver ( $\mathrm{CR}_{\mathrm{ss}} \mathrm{L}$ ) | 7.28 | 5 | - | - |  |
| Steady-state cell-water concentration ratio for gut ( $\mathrm{CR}_{\text {ss }} \mathrm{G}$ ) | 3.75 | 5 | - | - |  |
| Renal clearance rate constant ( $\mathrm{b}_{\text {clear }}$ ) | $0.07 \mathrm{~s}^{-1}$ | 5 | - | - |  |
| Renal reabsorption rate constant ( $\mathrm{b}_{\text {reab }}$ ) | $0.15 \mathrm{~s}^{-1}$ | 5 | - | - |  |
| Renal efflux rate constant ( $\mathrm{b}_{\text {efflux }}$ ) | $0.01 \mathrm{~s}^{-1}$ | 5 | - | - |  |



Figure S1. Correlation analysis between each sampled model parameter and PFOA concentration in blood after 12 days. '*' indicates $\mathrm{P}<0.05$. The correlation coefficient is the average of three simulation results at different dose and administration routes ( $1 \mathrm{mg} / \mathrm{kg}$ oral dose, $1 \mathrm{mg} / \mathrm{kg}$ IV dose and $0.1 \mathrm{mg} / \mathrm{kg}$ oral dose), given that the sensitivities were similar for the three scenarios.


Figure S2. Correlation analysis between each sampled model parameter and PFOA concentration in kidney after 12 days. '*' indicates $\mathrm{P}<0.05$. Correlation coefficient is the average of three simulation results at different dose and administration routes ( $1 \mathrm{mg} / \mathrm{kg}$ oral dose, $1 \mathrm{mg} / \mathrm{kg}$ IV dose and $0.1 \mathrm{mg} / \mathrm{kg}$ oral dose), given that the sensitivities were similar for the three scenarios.


Figure S3. Correlation analysis between each sampled model parameter and PFOA concentration in liver after 12 days. '*' indicates $\mathrm{P}<0.05$. Correlation coefficient is the average of three simulation results at different dose and administration routes ( $1 \mathrm{mg} / \mathrm{kg}$ oral dose, $1 \mathrm{mg} / \mathrm{kg}$ IV dose and $0.1 \mathrm{mg} / \mathrm{kg}$ oral dose), given that the sensitivities were similar for the three scenarios.

## S5 PFOA Concentration Profile in Compartments.

The predicted PFOA concentration profile in tissue compartments for different dose scenarios are shown in Figures S4-S6. We only had experimental data at single time points, but here we show model prediction as a function of time and can show that experimental data fall within the $95 \%$ confidence interval.

Standard toxicokinetic parameters were also calculated based on model predictions (Table S8).

Table S8. Toxicokinetic parameters comparison between prediction and experimental data

| Toxicokinetic | 01ppm oral ${ }^{\mathrm{a}}$ |  | 1ppm oral ${ }^{\mathrm{a}}$ |  | 1ppm IV ${ }^{\mathrm{a}}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | predicted | experimental | predicted | experimental | predicted | experimental |
|  | value | data | value | data | value | data |
| Cmax (ng/g) | 311.20 | $598 \pm 127$ | 2810.00 | $8431 \pm 1161$ | - | - |
| Tmax (h) | 5.80 | $10.25 \pm 6.45$ | 5.80 | $9.00 \pm 3.83$ | - | - |
| half-life (day) | 6.80 | $8.41 \pm 1.56$ | 6.93 | $5.76 \pm 1.33$ | 6.93 | $7.73 \pm 0.82$ |
| Clearance (mL/kg/day) | 62.67 | $23.10 \pm 5.76$ | 69.64 | $20.9 \pm 3.79$ | 69.45 | $21.51 \pm 1.97$ |
| a the experimental data are extracted from the Kemper study ${ }^{33}$ |  |  |  |  |  |  |



Figure S4. Concentration profile as a function of time for PFOA in different compartments after a single oral dose of $1 \mathrm{mg} / \mathrm{kg}$. The upper and lower dotted lines represent the $97.5^{\text {th }}$ percentile and $2.5^{\text {th }}$ percentile of predicted results, respectively; the solid line corresponds to geometric mean values. ' $o$ ' is the experimental data from the Kim et $\mathrm{al}^{37}$ study, and '*' indicates the data from the Kemper's ${ }^{33}$ study.


Figure S5. Concentration profile as a function of time for PFOA in different compartments after a single IV dose of $1 \mathrm{mg} / \mathrm{kg}$. The upper and lower dotted lines represent the $97.5^{\text {th }}$ percentile and $2.5^{\text {th }}$ percentile of predicted results, respectively; the solid line corresponds to geometric mean values. ' $o$ ' is the experimental data from the Kim et al ${ }^{37}$ study.


Figure S6. Concentration profile as a function of time for PFOA in different compartments after a single IV dose of $0.041 \mathrm{mg} / \mathrm{kg}$. The upper and lower dotted lines represent the $97.5^{\text {th }}$ percentile and $2.5^{\text {th }}$ percentile of predicted results, respectively; the solid line corresponds to geometric mean values. Red dot indicates the experimental data from the Kudo et al. ${ }^{38}$ study.

## S6 PBPK Model Code.

The PBPK model developed in this study was programmed in MATLAB (MATLAB R2016a); the code for the Kemper IV dose simulation follows as an illustrative example.

## References

(1) Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10 (7), 1093-1095.
(2) Brown, R. P.; Delp, M. D.; Lindstedt, S. L.; Rhomberg, L. R.; Beliles, R. P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13 (4), 407-484.
(3) Blouin, A.; Bolender, R. P.; Weibel, E. R. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J. Cell Biol. 1977, 72 (2), 441-455.
(4) Larson, M.; Sjöquist, M.; Wolgast, M. Renal interstitial volume of the rat kidney. Acta Physiol. Scand. 1984, 120 (2), 297-304.
(5) Barratt, T. M.; Walser, M. Extracellular fluid in individual tissues and in whole animals: the distribution of radiosulfate and radiobromide. J. Clin. Invest. 1969, 48 (1), 56.
(6) Ng, C. A.; Hungerbühler, K. Bioconcentration of perfluorinated alkyl acids: how important is specific binding? Environ. Sci. Technol. 2013, 47 (13), 7214-7223.
(7) Everett, N. B.; Simmons, B.; Lasher, E. P. Distribution of blood (Fe59) and plasma (I131) volumes of rats determined by liquid nitrogen freezing. Circul. Res. 1956, 4, 419-424.
(8) Crone, C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion'method. Acta Physiol. Scand. 1963, 58 (4), 292-305.
(9) McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in - vivo experiments. J. Pharm. Pharmacol. 2008, 60 (1), 63-70.
(10) Munger, K.; Baylis, C. Sex differences in renal hemodynamics in rats. Am. J. Physiol. Renal Physiol. 1988, 254 (2), F223-F231.
(11) Biewald, N.; Billmeier, J. Blood volume and extracellular space (ECS) of the whole body and some organs of the rat. Experientia 1978, 34 (3), 412-413.
(12) Kirkman, H.; Stowell, R. Renal filtration surface in the albino rat. Anat. Rec. 1942, 82 (3), 373-391.
(13) DeSesso, J.; Jacobson, C. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 2001, 39 (3), 209-228.
(14) Arthur, S.; Green, R. Fluid reabsorption by the proximal convoluted tubule of the kidney in lactating rats. J. Physiol. 1986, 371, 267.
(15) Bonvalet, J.; de Rouffignac, C. Distribution of ferrocyanide along the proximal tubular lumen of the rat kidney: its implications upon hydrodynamics. J. Physiol. 1981, 318, 85.
(16) Frazier, K. S.; Seely, J. C.; Hard, G. C.; Betton, G.; Burnett, R.; Nakatsuji, S.; Nishikawa, A.; Durchfeld-Meyer, B.; Bube, A. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol. Pathol. 2012, 40 (4 suppl), 14S-86S.
(17) Kanauchi, O.; Agata, K.; Fushiki, T. Mechanism for the increased defecation and jejunum mucosal protein content in rats by feeding germinated barley foodstuff. Biosci., Biotechnol., Biochem. 1997, 61 (3), 443-448.
(18) Cavigelli, S.; Monfort, S.; Whitney, T.; Mechref, Y.; Novotny, M.; McClintock, M. Frequent serial fecal corticoid measures from rats reflect circadian and ovarian corticosterone rhythms. J. Endocrinol. 2005, 184 (1), 153-163.
(19) Crisman, T. S.; Claffey, K. P.; Saouaf, R.; Hanspal, J.; Brecher, P. Measurement of rat heart fatty acid binding protein by ELISA. Tissue distribution, developmental changes and subcellular distribution. J. Mol. Cell. Cardiol. 1987, 19 (5), 423-431.
(20) Levitt, D. G. The pharmacokinetics of the interstitial space in humans. BMC Clin. Pharmacol. 2003, 3 (1), 3 .
(21) Ockner, R. K.; Manning, J.; Kane, J. Fatty acid binding protein. Isolation from rat liver, characterization, and immunochemical quantification. J. Biol. Chem. 1982, 257 (13), 7872-7878.
(22) Maatman, R. G.; van de Westerlo, E. M.; Van Kuppevelt, T.; Veerkamp, J. H. Molecular identification of the liver-and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem. J. 1992, 288 (1), 285-290.
(23) Kimura, H.; Odani, S.; Nishi, S.; Sato, H.; Arakawa, M.; Ono, T. Primary structure and cellular distribution of two fatty acid-binding proteins in adult rat kidneys. J. Biol. Chem. 1991, 266 (9), 5963-5972.
(24) Ellmerer, M.; Schaupp, L.; Brunner, G. A.; Sendlhofer, G.; Wutte, A.; Wach, P.; Pieber, T. R. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am. J. Physiol. Endocrinol. Metab. 2000, 278 (2), E352-E356.
(25) Peters, T. The biosynthesis of rat serum albumin II. Intracellular phenomena in the secretion of newly formed albumin. J. Biol. Chem. 1962, 237 (4), 1186-1189.
(26) Han, X.; Snow, T. A.; Kemper, R. A.; Jepson, G. W. Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem. Res. Toxicol. 2003, 16 (6), 775-781.
(27) Woodcroft, M. W.; Ellis, D. A.; Rafferty, S. P.; Burns, D. C.; March, R. E.; Stock, N. L.; Trumpour, K. S.; Yee, J.; Munro, K. Experimental characterization of the mechanism of perfluorocarboxylic acids' liver protein bioaccumulation: The key role of the neutral species. Environ. Toxicol. Chem. 2010, 29 (8), 16691677.
(28) Han, X.; Hinderliter, P. M.; Snow, T. A.; Jepson, G. W. Binding of Perfluorooctanoic Acid to Rat Liver - form and Kidney - form a 2 u - Globulins. Drug Chem. Toxicol. 2004, 27 (4), 341-360.
(29) Weaver, Y. M.; Ehresman, D. J.; Butenhoff, J. L.; Hagenbuch, B. Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicol. Sci. 2009, kfp275.
(30) Zhao, W.; Zitzow, J. D.; Ehresman, D. J.; Chang, S.-C.; Butenhoff, J. L.; Forster, J.; Hagenbuch, B. $\mathrm{Na}+/$ taurocholate cotransporting polypeptide and apical sodium-dependent bile acid transporter are involved in the disposition of perfluoroalkyl sulfonates in humans and rats. Toxicol. Sci. 2015, kfv102.
(31) Han, X.; Nabb, D. L.; Russell, M. H.; Kennedy, G. L.; Rickard, R. W. Renal elimination of perfluorocarboxylates (PFCAs). Chem. Res. Toxicol. 2011, 25 (1), 35-46.
(32) Yang, C.-H.; Glover, K. P.; Han, X. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol. Sci. 2010, 117 (2), 294-302.
(33) Kemper, R. A. Perfluorooctanoic acid: toxicokinetics in the rat. Project ID: DuPont 2003, 7473.
(34) MacLeod, M.; Fraser, A. J.; Mackay, D. Evaluating and expressing the propagation of uncertainty in chemical fate and bioaccumulation models. Environ. Toxicol. Chem. 2002, 21 (4), 700-709.
(35) Hebert, P. C.; MacManus-Spencer, L. A. Development of a fluorescence model for the binding of medium-to long-chain perfluoroalkyl acids to human serum albumin through a mechanistic evaluation of spectroscopic evidence. Anal. Chem. 2010, 82 (15), 6463-6471.
(36) Yang, Y.; Xu, X.; Georgopoulos, P. G. A Bayesian population PBPK model for multiroute chloroform exposure. J. Expo. Sci. Environ. Epidemiol. 2010, 20 (4), 326-341.
(37) Kim, S.-J.; Heo, S.-H.; Lee, D.-S.; Hwang, I. G.; Lee, Y.-B.; Cho, H.-Y. Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food Chem. Toxicol. 2016, 97, 243-255.
(38) Kudo, N.; Sakai, A.; Mitsumoto, A.; Hibino, Y.; Tsuda, T.; Kawashima, Y. Tissue distribution and hepatic subcellular distribution of perfluorooctanoic acid at low dose are different from those at high dose in rats. Biol. Pharm. Bull. 2007, 30 (8), 1535-1540.

1 \%\% Diffusion-Limited PBPK for PFOA in Male Rats
2 \%\% Code written by Weixiao Cheng, University of Pittsburgh
3 \%\% Last Modified: 26 July, 2017
4
$5 \%$ The purpose of this model is to predict the toxicokinetics and tissue $6 \%$ distributioin of PFOA in male rats without the need to fit experimental 7 \% data.

8
9 \% This version implements Monte Carlo uncertainty analysis. Parameter
10 \% values are therefore chosen from distributions (normal, lognormal,
$11 \%$ or uniform, see SI Section S4 for details) over 10,000 iterations.
12
13 \% The code below is parameterized to replicate the conditions of the $1 \mathrm{mg} / \mathrm{kg}$
14 \% IV dose experiment from Kemper (33).
15 \% For the code for other dose experiments, the paramters including body
16 \% weight(BW), Dose, and sampling time (seconds) need to be modified to
17 \% corresponding values based on different studies. Moreover, the initial
18 \% condition is different between IV and oral dose treatment. Namely, for IV
19 \% dose, the initial concentration of PFOA in the blood compartment is Dose
20 \% times BW (i.e., in line 311, y1 = Dose.*BW.*ones([1, Q])), with PFOA
21 \% concentration in other compartments being zero; for oral dose, the initial
22 \% concentration of PFOA in the gut lumen compartment is Dose time BW
23 \% (i.e.,in line 340, y26 = Dose.*BW.*ones([1,Q])), with PFOA in other
24 \% compartments being zero.
25 clc;
26 clear all;
27 close all;
28 Q = 10000; \% number of iterations for Monte Carlo analysis
$29 \mathrm{BW}=$ normrnd( $0.244,37 \mathrm{e}-3,1, \mathrm{Q}) ; \%$ body weight (kg)
30 Dose $=$ normrnd(1e-6,0.15e-6,1,Q); \% the unit is kg PFOA/kg BW
31
32
33 \% Volume of tissue i as percentage of body weight (PVi, unitless) and
34 \% volume (Vi, m^3), assuming the density of tissue is $1 e 3 \mathrm{~kg} / \mathrm{m} \wedge 3$.
$35 \mathrm{PVB}=\operatorname{lognrnd}\left(\log (54 \mathrm{e}-6), 0.5^{*} \log (1.7), 1, \mathrm{Q}\right)$;
36 VB = PVB.*BW; \% blood volume
37 PVplasma $=\operatorname{lognrnd}\left(\log (31.2 e-6), 0.5^{*} \log (1.7), 1, Q\right)$;
38 Vplasma = PVplasma.*BW; \% plasma volume
39 PVK $=\operatorname{lognrnd}\left(\log (0.73 / 100 / 1 e 3), 0.5^{*} \log (1.4), 1, Q\right)$;
40 VK = PVK.*BW; \% kidney volume
PVKB $=\operatorname{lognrnd}\left(\log (0.16), 0.5^{*} \log (1.6), 1, Q\right) ;$
VKB = PVKB.*PVK.*BW; \% kidney blood volume
PVKF $=\operatorname{lognrnd}\left(\log (0.13), 0.5^{*} \log (1.6), 1, Q\right) ;$
VKF = PVKF.*PVK.*BW; \% kidney interstitial fluid volume
VKT = VK - VKF; \% kidney tissue volume
VFil $=\operatorname{lognrnd}\left(\log (0.25 / 1 e 6), 0.5^{*} \log (1.7), 1, Q\right) ; \%$ renal filtrate volume
PVL $=\log n r n d\left(\log (3.66 / 100 / 1 e 3), 0.5^{*} \log (1.6), 1, Q\right) ;$
VL $=$ PVL.*BW; \% liver volume
PVLB $=\operatorname{lognrnd}\left(\log (0.21), 0.5^{*} \log (1.5), 1, Q\right) ;$
VLB $=$ PVLB. ${ }^{*}$ PVL.*BW; \% liver blood volume
PVLF $=\log n r n d\left(\log (0.049), 0.5^{*} \log (3), 1, Q\right)$;
VLF = PVLF.*PVL.*BW; \% liver interstitial fluid volume
VLT = VL - VLF; \% liver tissue volume
PVbile $=\operatorname{lognrnd}\left(\log (0.004), 0.5^{*} \log (1.7), 1, Q\right)$;

56 PVG $=\operatorname{lognrnd}\left(\log (2.69 / 100 / 1 e 3), 0.5^{*} \log (1.4), 1, Q\right)$;
7 VG = PVG.*BW; \% gut volume
58 PVGB $=\operatorname{lognrnd}\left(\log (0.034), 0.5^{*} \log (3), 1, Q\right)$;
59 VGB = PVGB.*PVG.*BW; \% gut blood volume
60 PVGF $=\operatorname{lognrnd}\left(\log (0.28), 0.5^{*} \log (1.5), 1, Q\right)$;
61 VGF = PVGF.*PVG.*BW; \% gut interstitial fluid volume
62 VGT = VG - VGF; \% gut tissue volume
PVGL $=\operatorname{lognrnd}\left(\log (4.5 / 100 / 1 e 3), 0.5^{*} \log (1.7), 1, Q\right) ;$
VGL = PVGL.*BW; \% gut lumen volume
PVM $=\operatorname{lognrnd}\left(\log (40.43 / 100 / 1 e 3), 0.5^{*} \log (1.1), 1, Q\right) ;$
VM $=$ PVM.*BW; \% muscle volume
PVMB $=\log n r n d\left(\log (0.04), 0.5^{*} \log (3), 1, Q\right) ;$
VMB = PVMB.*PVM.*BW; \% muscle blood volume
PVMF $=\operatorname{lognrnd}\left(\log (0.054), 0.5^{*} \log (3), 1, Q\right) ;$
VMF = PVMF.*PVM.*BW; \% muscle interstitial fluid volume
VMT = VM - VMF; \% muscle tissue volume
PVA $=\operatorname{lognrnd}\left(\log (7 / 100 / 1 e 3), 0.5^{*} \log (1.7), 1, Q\right)$;
VA = PVA.*BW; \% adipose volume
PVAB $=\log n r n d\left(\log (0.02), 0.5^{*} \log (3), 1, Q\right) ;$
VAB = PVAB. *PVA. *BW; \% adipose blood volume
PVAF $=\log n r n d\left(\log (0.174), 0.5^{*} \log (1.6), 1, Q\right) ;$
VAF = PVAF.*PVA.*BW; \% adipose interstitial fluid volume
VAT = VA - VAF; \% adipose tissue volume

VR = PVR.*BW; \% volume of the rest of body
PVRB $=\operatorname{lognrnd}\left(\log (0.036), 0.5^{*} \log (3), 1, Q\right) ;$
VRB = PVRB. ${ }^{*}$ PVR.*BW; \% volume of the blood of the rest of body
PVRF $=\log n r n d\left(\log (0.18), 0.5^{*} \log (1.6), 1, Q\right) ;$
VRF = PVRF.*PVR.*BW; \% interstitial fluid volume of the rest of body
VRT = VR - VRF; \% tissue volume of the rest of body
86
87
88 \% Capillary surface area for each tissue (Ai) as percentage of body weight
$9 \%$ or weight of corresponding tissue (PAi, unitless) and surface area (m^2).
PAK $=\log n r n d\left(\log (350 e-4), 0.5^{*} \log (3), 1, Q\right)$;
AK = PAK.*VK.*10^6; \% kidney surface area
PAKG $=\operatorname{lognrnd}\left(\log (6890 / 1 \mathrm{e} 6), 0.5^{*} \log (3), 1, Q\right) ;$
AKG $=$ PAKG.*VK.*10^6; \% the surface area of glomerular capillary
PAL $=\operatorname{lognrnd}\left(\log (250 \mathrm{e}-4), 0.5^{*} \log (3), 1, Q\right) ;$
AL $=$ PAL. ${ }^{* V L . * 10 \wedge 6 ; ~ \% ~ l i v e r ~ s u r f a c e ~ a r e a ~}$
PAG $=\operatorname{lognrnd}\left(\log (100 e-4), 0.5^{*} \log (3), 1, Q\right) ;$
AG $=$ PAG.*VG.*10^6; \% gut surface area
PAGL $=\operatorname{lognrnd}\left(\log (4.14), 0.5^{*} \log (3), 1, Q\right)$;
AGL = PAGL.*BW; \% gut lumen surface area
PAM $=\operatorname{lognrnd}\left(\log (70 \mathrm{e}-4), 0.5^{*} \log (3), 1, Q\right) ;$
AM = PAM.*VM.*10^6; \% muscle surface area
$\mathrm{PAA}=\operatorname{lognrnd}\left(\log (70 \mathrm{e}-4), 0.5^{*} \log (3), 1, \mathrm{Q}\right)$;
$A A=P A A . * V A .{ }^{*} 10 \wedge 6 ; \%$ adipose surface area
PAR $=\log n r n d\left(\log (100 e-4), 0.5^{*} \log (3), 1, Q\right) ;$
AR $=$ PAR. ${ }^{*} V R .{ }^{*} 10 \wedge 6 ; \%$ surface area of rest of body

```
109
110 PeffB = lognrnd(log(4.98e-8),0.5*log(5),1,Q);
111 PeffK = lognrnd(log(4.38e-8),0.5* log(5),1,Q);
112 PeffL = lognrnd(log(5.15e-8),0.5*log(5),1,Q);
113 PeffG = lognrnd(log(2.65e-8),0.5*log(5),1,Q);
114 PeffA = lognrnd(log(2.65e-8),0.5* log(5),1,Q);
115 PeffM = lognrnd(log(2.65e-8),0.5*log(5),1,Q);
116 PeffR = lognrnd(log(2.65e-8),0.5*log(5),1,Q);
117
1 1 8 \% ~ S t e a d y - s t a t e ~ c e l l - w a t e r ~ c o n c e n t r a t i o n ~ r a t i o s ( C R s s ) ~ f o r ~ g u t , ~ l i v e r , ~ a n d
119 % kidney.
120 CRssG = lognrnd(log(3.75),0.5* log(5),1,Q);
121 CRssL = lognrnd(log(7.28),0.5* log(5),1,Q);
122 CRssK = lognrnd(log(6.19),0.5*log(5),1,Q);
123
124
125 % Blood flow rates (QBi, in m^3/s) to different tissues (i=L, K, G, A, M, R)
126 % as a percentage of cardiac output (Qcardiac), which itself is a function
127 % of body weight (BW).
128 Qcardiac = 0.235/60*1e-3*BW.^0.75;
129 PQBK = lognrnd(log(14.1/100),0.5*log(1.4),1,Q);
130 QBK = PQBK.*Qcardiac;
131 PQBG = lognrnd(log(15.1/100),0.5*log(1.3),1,Q);
132 QBG = PQBG.*Qcardiac;
133 PQBL = lognrnd(log(2.4/100),0.5* log(2.7),1,Q);
134 QBL = (PQBL+PQBG).*Qcardiac;
135 PQBM = lognrnd(log(27.8/100),0.5* log(1.3),1,Q);
136 QBM = PQBM.*Qcardiac;
137 PQBA = lognrnd(log(7/100),0.5*log(1.3),1,Q);
138 QBA = PQBA.*Qcardiac;
139 PQBR = 1 - PQBK - PQBG - PQBL - PQBM - PQBA;
140 QBR = PQBR.*Qcardiac;
141 % Flow rate of fluids including feces, bile, urine and glomerular filtration
142 % rate (GFR), in m^3/s.
143 Qfeces = lognrnd(log(5.63*1e-6/(24*3600)),0.5* log(2.7),1,Q);
1 5 2 ~ \% ~ A l b u m i n ~ c o n c e n t r a t i o n ~ i n ~ b l o o d ~ a n d ~ i n t e r s t i t i a l ~ f l u i d ~ c o m p a r t m e n t s ( m o l / m \wedge 3 ) .
153 CalbB = lognrnd(log(281e-3*7.8),0.5* log(3),1,Q);
154 CalbKF = lognrnd(log(243e-3*7.8),0.5* log(3),1,Q);
155 CalbLF = lognrnd(log(243e-3*7.8),0.5* log(3),1,Q);
156 CalbGF = lognrnd(log(146e-3*7.8),0.5* log(3),1,Q);
157 CalbMF = lognrnd(log(146e-3*7.8),0.5* log(3),1,Q);
158 CalbAF = lognrnd(log(73e-3*7.8),0.5* log(3),1,Q);
159 CalbRF = lognrnd(log(73e-3*7.8),0.5* log(3),1,Q);
160
161 % Alpha2mu-globulin concentration in kidney tissue (mol/m^3).
162 Ca2uKT = lognrnd(log(110e-3),0.5* log(3),1,Q);
```

164 \% LFABP concentration in kidney and liver tissue (mol/m^3).
165 CL_fabpKT $=\operatorname{lognrnd}\left(\log (2.65 e-3 * 3), 0.5^{*} \log (3), 1, Q\right)$;
166 CL_fabpKT1 = CL_fabpKT./3;
167 CL_fabpKT2 = CL_fabpKT./3;
168 CL_fabpKT3 = CL_fabpKT./3;
169 CL_fabpLT $=\operatorname{lognrnd}\left(\log \left(133 e-3^{*} 3\right), 0.5^{*} \log (3), 1, Q\right)$;
170 CL_fabpLT1 = CL_fabpLT./3;
171 CL_fabpLT2 = CL_fabpLT./3;
172 CL_fabpLT3 = CL_fabpLT./3;
173
174
175 \% Equilibrium association constant (m^3/mol) for albumin(Ka), LFABP(KL_fabp),
176 \% and alpha2mu-globulin(Ka2u). See SI section S2-2 for details.
$177 \mathrm{Ka}=\operatorname{lognrnd}\left(\log (3.1), 0.5^{*} \log (3.5), 1, Q\right)$;
178 KL_fabp1 = lognrnd(log(120),0.5* $\log (3.5), 1, Q) ;$
179 KL_fabp2 = lognrnd(log(40.0),0.5*log(3.5),1,Q);
$180 \mathrm{KL} \_$fabp3 $=\operatorname{lognrnd}\left(\log (19.0), 0.5^{*} \log (3.5), 1, Q\right)$;
$181 \mathrm{Ka} 2 \mathrm{u}=\operatorname{lognr} \mathrm{nd}\left(\log (0.5), 0.5^{*} \log (3.5), 1, \mathrm{Q}\right)$;
182 \% Individual rate constants for association and dissociation(s^-1 and m^3/mol*s).
183 \% Note kon/koff=Keq.
184 koff $=$ unifrnd(0.001,0.1,1,Q); \% assume koff is 0.01/s
185 kon = koff.*Ka;
186 kL_fabpon1 = koff.*KL_fabp1;
187 kL_fabpon2 = koff.*KL_fabp2;
188 kL_fabpon3 = koff.*KL_fabp3;
189 kK_fabpon $=$ koff.*Ka2u;
190
191
192 \% Overall mass transfer coefficients between subcompartments and passive
193 \% diffusion rate constants. See SI section S3-1 for details.
194 kBKF = ((1./QBK) + 1./(PeffB.*AK)).^(-1);
195 kBF = PeffB.*AKG;
196 kKFKT = PeffK.*AK;
$197 \mathrm{n}=\operatorname{lognrnd}\left(\log (5), 0.5^{*} \log (3), 1, Q\right) ; \%$ enlargement factor of apical membrane ofk
proximal tubule
198 kFKT = PeffK.*AK.*n;
199 kBLF $=((1 . / Q B L)+1 . /(P e f f B . * A L)) . \wedge(-1) ;$
200
201
kbileLT = PeffL.*AL
211
212 \% First-order rate constants (s^-1).
213 bBKF = kBKF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
214 bKFB = kBKF./VKF;
215 bKFKT = kKFKT./VKF;

```
216 bKTKF = kKFKT./VKT;
217 bFKT = kFKT./VFil;
218 bKTF = kFKT./(VKT.*CRssK);
219 bBF = QGFR./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
220 bFB = kBF./VFil;
221 bBLF = kBLF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
222 bLFB = kBLF./VLF;
223 bLFLT = kLFLT./VLF;
224 bLTLF = kLFLT./VLT;
225 bbileLT = kbileLT./Vbile;
226 bLTbile = kbileLT./(VLT.*CRssL);
227 bBGF = kBGF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
228 bGFB = kBGF./VGF;
229 bGFGT = kGFGT./VGF;
230 bGTGF = kGFGT./VGT;
231 bGLGT = kGLGT./VGL;
232 bGTGL = kGLGT./(VGT.*CRssG);
233 bBMF = kBMF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
234 bMFB = kBMF./VMF;
235 bMFMT = kMFMT./VMF;
236 bMTMF = kMFMT./VMT;
237 bBAF = kBAF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
238 bAFB = kBAF./VAF;
239 bAFAT = kAFAT./VAF;
240 bATAF = kAFAT./VAT;
241 bBRF = kBRF./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
242 bRFB = kBRF./VRF;
243 bRFRT = kRFRT./VRF;
244 bRTRF = kRFRT./VRT;
245
246
247 % First-order rate constants (s^-1) for protein-mediated transport, see
248 % section S3-3 for details.
249 Pbclear = lognrnd(log(2.76e-7),0.5* log(5),1,Q);
250 bclear = Pbclear.*AK./VKF;
251 Pbreab = lognrnd(log(1.18e-7),0.5*log(5),1,Q);
2 5 2 ~ b r e a b ~ = ~ n . * P b r e a b . * A K . / V F i l ; ~
253 Pbabs = lognrnd(log(1.78e-7),0.5*log(5),1,Q);
254 babs = Pbabs.*AL./VLF;
255 Pbefflux = lognrnd(log(1.38e-7),0.5*log(5),1,Q);
256 befflux = Pbefflux.*AK./VKT;
257
258
259 % Conversion between mass and concentration for protein content of tissues.
260 MalbB = CalbB.*(VB+VLB+VKB+VGB+VMB+VAB+VRB);
261 MalbKF = CalbKF.*VKF;
262 ML_fabpKT1 = CL_fabpKT1.*VKT;
263 ML_fabpKT2 = CL_fabpKT2.*VKT;
264 ML_fabpKT3 = CL_fabpKT3.*VKT;
265 MK_fabpKT = Ca2uKT.*VKT;
266 MalbLF = CalbLF.*VLF;
267 ML_fabpLT1 = CL_fabpLT1.*VLT;
268 ML_fabpLT2 = CL_fabpLT2.*VLT;
269
ML_fabpLT3 = CL_fabpLT3.*VLT;
```

270 MalbGF = CalbGF.*VGF;
271 MalbMF = CalbMF.*VMF;
272 MalbAF = CalbAF.*VAF;
273 MalbRF = CalbRF.*VRF;
274
275
276 \% Below is the numerical method used to solve mass balance equations.
277 seconds = 22*24*3600; \% simulation time, 22 days
278 h = 0.07; \% step size
279 tspan = (1:h:seconds);
280 steps $=$ seconds./h;
281
282 \% Initial condition for each comparment.
283 \% Mass of PFOA in blood not bound to proteins: y1
284 \% Mass of PFOA in blood bound to albumin: y2
285 \% Mass of PFOA in interstitial fluid of kidney not bound to proteins: y3
286 \% Mass of PFOA in interstitial fluid of kidney bound to albumin: y4
287 \% Mass of PFOA in kidney tissue not bound to proteins: y5
288 \% Mass of PFOA in kidney tissue bound to LFABP: y6, y61, and y62 (LFABP
289 \% has 3 binding sites)
290 \% Mass of PFOA in kidney tissue bound to alpha2mu-globulin: y7
291 \% Mass of PFOA in renal filtrate not bound to proteins: y8
292 \% Mass of PFOA in interstitial fluid of liver not bound to proteins: y9
293 \% Mass of PFOA in interstitial fluid of liver bound to albumin: y10
294 \% Mass of PFOA in liver tissue not bound to proteins: y11
295 \% Mass of PFOA in liver tissue bound to LFABP: y12, y121, and y122 (LFABP
296 \% has 3 binding sites)
297 \% Mass of PFOA in bile not bound to proteins: y13
298 \% Mass of PFOA in interstitial fluid of gut not bound to proteins: y14
299 \% Mass of PFOA in interstitial fluid of gut bound to albumin: y15
300 \% Mass of PFOA in gut tissue not bound to proteins: y16
301 \% Mass of PFOA in interstitial fluid of muscle not bound to proteins: y17
302 \% Mass of PFOA in interstitial fluid of muscle bound to albumin: y18
303 \% Mass of PFOA in muscle tissue not bound to proteins: y19
304 \% Mass of PFOA in interstitial fluid of adipose not bound to proteins: y20
305 \% Mass of PFOA in interstitial fluid of adipose bound to albumin: y21
306 \% Mass of PFOA in adipose tissue not bound to proteins: y22
307 \% Mass of PFOA in interstitial fluid of the rest of body not bound to proteinsk
y23
308 \% Mass of PFOA in interstitial fluid of the rest of body bound to albumin: y24
309 \% Mass of PFOA in tissue of the rest of body not bound to proteins: y25
310 \% Mass of PFOA in gut lumen not bound to proteins: y26
311 y1 = Dose.*BW.*ones([1, Q]);
312 y2 $=\operatorname{zeros}([1, Q])$;
313 y3 = zeros([1,Q]);
314 y4 = zeros([1,Q]);
315 y5 = zeros([1,Q]);
316 y6 = zeros([1,Q]);
317 y61 $=\operatorname{zeros}([1, Q])$;
318 y62 = zeros([1, Q]);
319 y7 = zeros([1,Q]);
320 y8 = zeros([1, Q]);
321 y9 = zeros([1,Q]);
322 y10 = zeros([1,Q]);
341
356
357
358
359
360
361
362
363
/VLT);

```
```

```
323 y11 = zeros([1,Q]);
```

```
323 y11 = zeros([1,Q]);
324 y12 = zeros([1,Q]);
324 y12 = zeros([1,Q]);
325 y121 = zeros([1,Q]);
325 y121 = zeros([1,Q]);
326 y122 = zeros([1,Q]);
326 y122 = zeros([1,Q]);
327 y13 = zeros([1,Q]);
327 y13 = zeros([1,Q]);
328 y14 = zeros([1,Q]);
328 y14 = zeros([1,Q]);
329 y15 = zeros([1,Q]);
329 y15 = zeros([1,Q]);
330 y16 = zeros([1,Q]);
330 y16 = zeros([1,Q]);
331 y17 = zeros([1,Q]);
331 y17 = zeros([1,Q]);
332 y18 = zeros([1,Q]);
332 y18 = zeros([1,Q]);
333 y19 = zeros([1,Q]);
333 y19 = zeros([1,Q]);
334 y20 = zeros([1,Q]);
334 y20 = zeros([1,Q]);
335 y21 = zeros([1,Q]);
335 y21 = zeros([1,Q]);
336 y22 = zeros([1,Q]);
336 y22 = zeros([1,Q]);
337 y23 = zeros([1,Q]);
337 y23 = zeros([1,Q]);
338 y24 = zeros([1,Q]);
338 y24 = zeros([1,Q]);
339 y25 = zeros([1,Q]);
339 y25 = zeros([1,Q]);
340 y26 = zeros([1,Q]);
340 y26 = zeros([1,Q]);
342 for j = 1:steps
342 for j = 1:steps
343 % Mass balance for available protein binding sites.
343 % Mass balance for available protein binding sites.
344 MalbB_new = MalbB+h.*(koff.*y2-kon.*MalbB.*y1./(VB+VLB+VKB+VGB+VMB+VAB+VRB));
344 MalbB_new = MalbB+h.*(koff.*y2-kon.*MalbB.*y1./(VB+VLB+VKB+VGB+VMB+VAB+VRB));
345 MalbB = MalbB_new;
345 MalbB = MalbB_new;
346 CalbB = MalbB./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
346 CalbB = MalbB./(VB+VLB+VKB+VGB+VMB+VAB+VRB);
347 MalbKF_new = MalbKF+h.*(koff.*y4-kon.*MalbKF.*y3./VKF);
347 MalbKF_new = MalbKF+h.*(koff.*y4-kon.*MalbKF.*y3./VKF);
348 MalbKF = MalbKF_new;
348 MalbKF = MalbKF_new;
349 CalbKF = MalbKF./VKF;
349 CalbKF = MalbKF./VKF;
350 ML_fabpKT1_new = ML_fabpKT1+h.*(koff.*y6-kL_fabpon1.*ML_fabpKT1.*y5./VKT);
350 ML_fabpKT1_new = ML_fabpKT1+h.*(koff.*y6-kL_fabpon1.*ML_fabpKT1.*y5./VKT);
351 ML_fabpKT1 = ML_fabpKT1_new;
351 ML_fabpKT1 = ML_fabpKT1_new;
352 CL_fabpKT1 = ML_fabpKT1./VKT;
352 CL_fabpKT1 = ML_fabpKT1./VKT;
353 ML_fabpKT2_new = ML_fabpKT2+h.*(koff.*y61-kL_fabpon2.*ML_fabpKT2.*y5./VKT);
353 ML_fabpKT2_new = ML_fabpKT2+h.*(koff.*y61-kL_fabpon2.*ML_fabpKT2.*y5./VKT);
354 ML_fabpKT2 = ML_fabpKT2_new;
354 ML_fabpKT2 = ML_fabpKT2_new;
355 CL_fabpKT2 = ML_fabpKT2./VKT;
355 CL_fabpKT2 = ML_fabpKT2./VKT;
```

34
ML_fabpKT3_new = ML_fabpKT3+h.*(koff.*y62-kL_fabpon3.*ML_fabpKT3.*y5./VKT);
ML_fabpKT3_new = ML_fabpKT3+h.*(koff.*y62-kL_fabpon3.*ML_fabpKT3.*y5./VKT);
ML_fabpKT3 = ML_fabpKT3_new;
ML_fabpKT3 = ML_fabpKT3_new;
CL_fabpKT3 = ML_fabpKT3./VKT;
CL_fabpKT3 = ML_fabpKT3./VKT;
MK_fabpKT_new = MK_fabpKT+h.*(koff.*y7-kK_fabpon.*MK_fabpKT.*y5./VKT);
MK_fabpKT_new = MK_fabpKT+h.*(koff.*y7-kK_fabpon.*MK_fabpKT.*y5./VKT);
MK_fabpKT = MK_fabpKT_new;
MK_fabpKT = MK_fabpKT_new;
Ca2uKT = MK_fabpKT./VKT;
Ca2uKT = MK_fabpKT./VKT;
MalbLF_new = MalbLF+h.*(koff.*y10-kon.*MalbLF.*y9./VLF);
MalbLF_new = MalbLF+h.*(koff.*y10-kon.*MalbLF.*y9./VLF);
MalbLF = MalbLF_new;
MalbLF = MalbLF_new;
CalbLF = MalbLF./VLF;
CalbLF = MalbLF./VLF;
ML_fabpLT1_new = ML_fabpLT1 + h.*(koff.*y12 - kL_fabpon1.*ML_fabpLT1.*y11k
ML_fabpLT1_new = ML_fabpLT1 + h.*(koff.*y12 - kL_fabpon1.*ML_fabpLT1.*y11k
ML_fabpLT1 = ML_fabpLT1_new;
ML_fabpLT1 = ML_fabpLT1_new;
CL_fabpLT1 = ML_fabpLT1./VLT;
CL_fabpLT1 = ML_fabpLT1./VLT;
ML_fabpLT2_new = ML_fabpLT2+h.*(koff.*y121-kL_fabpon2.*ML_fabpLT2.*y11./VLT);
ML_fabpLT2_new = ML_fabpLT2+h.*(koff.*y121-kL_fabpon2.*ML_fabpLT2.*y11./VLT);
ML_fabpLT2 = ML_fabpLT2_new;
ML_fabpLT2 = ML_fabpLT2_new;
CL_fabpLT2 = ML_fabpLT2./VLT;
CL_fabpLT2 = ML_fabpLT2./VLT;
ML_fabpLT3_new = ML_fabpLT3+h.*(koff.*y122-kL_fabpon3.*ML_fabpLT3.*y11./VLT);
ML_fabpLT3_new = ML_fabpLT3+h.*(koff.*y122-kL_fabpon3.*ML_fabpLT3.*y11./VLT);
ML_fabpLT3 = ML_fabpLT3_new;
ML_fabpLT3 = ML_fabpLT3_new;
CL_fabpLT3 = ML_fabpLT3./VLT;
CL_fabpLT3 = ML_fabpLT3./VLT;
MalbGF_new = MalbGF+h.*(koff.*y15-kon.*MalbGF.*y14./VGF);
MalbGF_new = MalbGF+h.*(koff.*y15-kon.*MalbGF.*y14./VGF);
MalbGF = MalbGF_new;

```
    MalbGF = MalbGF_new;
```

407 bAFon = CalbAF.*kon;
408 bAFoff = koff;
409
410
411
412
413
*y1+bFB. *y8+bGFB. *y14-bBGF. *y1+bMFB. *y17-bBMF . *y1+bAFB. *y20-bBAF . *y1+bRFB. *y23-bBRF $k$
*y1);
$414 \quad y 1=\max \left(y 1 \_n e w, 0\right)$;
415 y2_new = y2 + h.*(bBon.*y1-bBoff.*y2);
$416 \quad y 2=\max \left(y 2 \_n e w, 0\right)$;
417 y3_new = y3 + h.*(bBKF.*y1-bKFB.*y3+befflux. *y5+bKTKF.*y5-bKFKT. *y3-bcleark
*y3+bKFoff. *y4-bKFon. *y3) ;
418 y3 = max (y3_new, 0);
419 y4_new = y4 + h.*(bKFon.*y3-bKFoff. *y4);
$420 \quad y 4=\max \left(y 4 \_n e w, 0\right)$;
$421 \quad y 5 \_n e w=y 5+h . *(b K F K T . * y 3+b F K T . * y 8+b r e a b . * y 8+b c l e a r . * y 3-b e f f l u x . * y 5-b K T K F k$
*y5-bKTF. *y5+bL_fabpKToff. *y6-bL_fabpKTon1. *y5+bL_fabpKToff. *y61-bL_fabpKTon2k
*y5+bL_fabpKToff. *y62-bL_fabpKTon3. *y5+bK_fabpKToff. *y7-bK_fabpKTon. *y5) ;
$422 \quad y 5=\max \left(y 5 \_n e w, 0\right)$;
423 y6_new = y6 + h.*(bL_fabpKTon1. *y5-bL_fabpKToff. ${ }^{*} y 6$ );
$424 y$ y6 $=\max \left(y 6 \_n e w, 0\right)$;

425
432 y8 = max (y8_new, 0);
433 y9_new = y9 + h.*(bBLF.*y1-bLFB.*y9+bLTLF.*y11-bLFLT. *y9-babs. *y9-bLFonk
*y9+bLFoff. *y10) ;
$434 \quad y 9=\max \left(y 9 \_n e w, 0\right)$;
435 y10_new $=y 10+h . *\left(b L F o n .{ }^{*} y 9-b L F o f f .{ }^{*} y 10\right)$;
$436 \quad y 10=\max \left(y 10 \_n e w, 0\right)$;
437 y11_new = y11 + h.*(bLFLT. *y9+babs.*y9+bbileLT.*y13-bLTbile.*y11-bLTLF. *y11k
bL_fabpLTon1. *y11+bL_fabpLToff. *y12-bL_fabpLTon2. *y11+bL_fabpLToff. *y121
bL_fabpLTon3.*y11+bL_fabpLToff.*y122);
$438 \quad y 11=\max \left(y 11 \_n e w, 0\right)$;
439 y12_new = y12 + h.*(bL_fabpLTon1.*y11-bL_fabpLToff.*y12);
$440 \quad \mathrm{y} 12=\max \left(\mathrm{y} 12 \_\right.$new, 0$)$;
$441 \quad y 121 \_n e w=y 121+h . *\left(b L_{-} f a b p L T o n 2 . * y 11-b L \_f a b p L T o f f . * y 121\right)$;
$442 \quad y 121=\max \left(y 121 \_n e w, 0\right)$;
443 y122_new = y122 + h.*(bL_fabpLTon3.*y11-bL_fabpLToff. *y122);
$444 \quad y 122=\max \left(y 122 \_n e w, 0\right)$;
$445 \quad y 13 \_n e w=y 13+h . *(b L T b i l e . * y 11-b b i l e L T . * y 13-Q b i l e . * y 13 . / V b i l e) ;$
$446 \quad y 13=\max \left(y 13 \_n e w, 0\right)$;
447 y14_new = y14 + h. *(bBGF. *y1-bGFB. *y14+bGTGF. *y16-bGFGT. *y14-bGFonk
*y14+bGFoff.*y15);
$448 \quad y 14=\max \left(y 14 \_n e w, 0\right)$;
449 y15_new = y15 + h.*(bGFon.*y14-bGFoff.*y15);
$450 \quad y 15=\max \left(y 15 \_n e w, 0\right)$;
451 y16_new = y16 + h.*(bGFGT. *y14-bGTGF.*y16+bGLGT. *y26-bGTGL.*y16);
$452 \quad y 16=\max \left(y 16 \_n e w, 0\right)$;
453 y17_new = y17 + h.*(bBMF. *y1-bMFB. *y17+bMTMF. *y19-bMFMT. *y17-bMFonk
*y17+bMFoff.*y18);
$454 \quad y 17=\max \left(y 17 \_n e w, 0\right)$;
455 y18_new = y18 + h.*(bMFon.*y17-bMFoff.*y18);
$456 \quad y 18=\max \left(y 18 \_n e w, 0\right)$;
457 y19_new $=$ y19 + h.*(bMFMT. *y17-bMTMF. *y19);
458 y19 = max (y19_new, 0) ;
459 y20_new $=y 20+h .{ }^{*}\left(b B A F .{ }^{*} y 1-b A F B .{ }^{*} y 20+b A T A F . * y 22-b A F A T . * y 20-b A F o n k\right.$
*y20+bAFoff.*y21) ;
$460 \quad y 20=\max \left(y 20 \_n e w, 0\right)$;
461 y21_new = y21 + h.*(bAFon. *y20-bAFoff.*y21);
$462 \quad y 21=\max \left(y 21 \_n e w, 0\right)$;
$463 \quad$ y22_new $=y 22+h .{ }^{*}\left(\right.$ bAFAT. $\left.{ }^{*} y 20-b A T A F .{ }^{*} y 22\right)$;
$464 \quad y 22=\max \left(y 22 \_n e w, 0\right)$;
465 y23_new = y23 + h. *(bBRF. *y1-bRFB. *y23+bRTRF. *y25-bRFRT. *y23-bRFonk
*y23+bRFoff.*y24);
$466 \quad y 23=\max \left(y 23 \_n e w, 0\right)$;
467 y24_new = y24 + h.*(bRFon.*y23-bRFoff.*y24);
$468 \quad \mathrm{y} 24=\max \left(y 24 \_n e w, 0\right)$;
469 y25_new = y25 + h.*(bRFRT.*y23-bRTRF. *y25);
$470 \quad y 25=\max \left(y 25 \_n e w, 0\right)$;

471

```
y26_new = y26 + h.*(bGTGL.*y16-bGLGT.*y26+Qbile.*y13./Vbile-Qfeces.*y26k
```

/VGL);
$472 \mathrm{y} 26=\max \left(\mathrm{y} 26 \_\right.$new, 0$)$;
473
474
yBfree = y1;
475 yBbound = y2;
476 yKFfree = y3;
477 yKFbound = y4;
478 yKTfree = y5;
479 yKTLbound1 = y6;
$480 \quad$ yKTLbound2 $=y 61$;
481 yKTLbound3 = y62;
482 yKTKbound = y7;
483 yFfree = y8;
484 yLFfree = y9;
485 yLFbound = y10;
486 yLTfree = y11;
487 yLTbound1 = y12;
488 yLTbound2 = y121;
$489 \quad y L T b o u n d 3=y 122$;
490 yBile = y13;
491 yGFfree = y14;
492 yGFbound = y15;
493 yGTfree = y16;
494 yMFfree = y17;
495 yMFbound = y18;
496 yMTfree = y19;
497 yAFfree = y20;
498 yAFbound = y21;
499 yATfree = y22;
500 yRFfree = y23;
501 yRFbound = y24;
502 yRTfree = y25;
503 yGLfree = y26;
504
505 i $=$ round (1 + j./3600)
506 t(i,:) $=$ j*h./(24*3600);
507
508 \% Unit conversion from kg/m^3 to ng/g.
509 Blood(i,:) = (yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB).*VB./Vplasmak
*10^6;
510 Kidney (i,:) = ((yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB) $k$
*VKB+yKFfree+yKFbound+yKTfree+yKTLbound1+yKTLbound2+yKTLbound3+yKTKbound).
(VKB+VKT+VKF).*10^6;
511 Liver(i,:) = ((yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB)k
*VLB+yLFfree+yLFbound+yLTfree+yLTbound1+yLTbound2+yLTbound3)./(VLB+VLT+VLF). *10^6;
512 Gut (i, : ) = ( (yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB)k
*VGB+yGFfree+yGFbound+yGTfree)./(VGB+VGT+VGF). *10^6;
513 Muscle(i,:) = ((yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB)k
*VMB+yMFfree+yMFbound+yMTfree)./(VMB+VMT+VMF). *10^6;
514 Adipose(i,:) = ((yBfree+yBbound)./(VB+VLB+VKB+VGB+VMB+VAB+VRB) k
*VAB+yAFfree+yAFbound+yATfree)./(VAB+VAT+VAF). *10^6;
515 Rest $(i,:)=((y B f r e e+y B b o u n d) . /(V B+V L B+V K B+V G B+V M B+V A B+V R B) k$
*VRB+yRFfree+yRFbound+yRTfree)./(VRB+VRT+VRF). *10^6;

```
Urine(i,:) = yFfree./VFil.*10^6;
```


## References

(1) Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10 (7), 1093-1095.
(2) Brown, R. P.; Delp, M. D.; Lindstedt, S. L.; Rhomberg, L. R.; Beliles, R. P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13 (4), 407-484.
(3) Blouin, A.; Bolender, R. P.; Weibel, E. R. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J. Cell Biol. 1977, 72 (2), 441-455.
(4) Larson, M.; Sjöquist, M.; Wolgast, M. Renal interstitial volume of the rat kidney. Acta Physiol. Scand. 1984, 120 (2), 297-304.
(5) Barratt, T. M.; Walser, M. Extracellular fluid in individual tissues and in whole animals: the distribution of radiosulfate and radiobromide. J. Clin. Invest. 1969, 48 (1), 56.
(6) $\mathrm{Ng}, \mathrm{C} . \mathrm{A}$.; Hungerbühler, K. Bioconcentration of perfluorinated alkyl acids: how important is specific binding? Environ. Sci. Technol. 2013, 47 (13), 7214-7223.
(7) Everett, N. B.; Simmons, B.; Lasher, E. P. Distribution of blood (Fe59) and plasma (I131) volumes of rats determined by liquid nitrogen freezing. Circul. Res. 1956, 4, 419-424.
(8) Crone, C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion'method. Acta Physiol. Scand. 1963, 58 (4), 292-305.
(9) McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in - vivo experiments. J. Pharm. Pharmacol. 2008, 60 (1), 63-70.
(10) Munger, K.; Baylis, C. Sex differences in renal hemodynamics in rats. Am. J. Physiol. Renal Physiol. 1988, 254 (2), F223-F231.
(11) Biewald, N.; Billmeier, J. Blood volume and extracellular space (ECS) of the whole body and some organs of the rat. Experientia 1978, 34 (3), 412-413.
(12) Kirkman, H.; Stowell, R. Renal filtration surface in the albino rat. Anat. Rec. 1942, 82 (3), 373-391.
(13) DeSesso, J.; Jacobson, C. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 2001, 39 (3), 209-228.
(14) Arthur, S.; Green, R. Fluid reabsorption by the proximal convoluted tubule of the kidney in lactating
rats. J. Physiol. 1986, 371, 267.
(15) Bonvalet, J.; de Rouffignac, C. Distribution of ferrocyanide along the proximal tubular lumen of the rat kidney: its implications upon hydrodynamics. J. Physiol. 1981, 318, 85.
(16) Frazier, K. S.; Seely, J. C.; Hard, G. C.; Betton, G.; Burnett, R.; Nakatsuji, S.; Nishikawa, A.; DurchfeldMeyer, B.; Bube, A. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol. Pathol. 2012, 40 (4 suppl), 14S-86S.
(17) Kanauchi, O.; Agata, K.; Fushiki, T. Mechanism for the increased defecation and jejunum mucosal protein content in rats by feeding germinated barley foodstuff. Biosci., Biotechnol., Biochem. 1997, 61 (3), 443-448.
(18) Cavigelli, S.; Monfort, S.; Whitney, T.; Mechref, Y.; Novotny, M.; McClintock, M. Frequent serial fecal corticoid measures from rats reflect circadian and ovarian corticosterone rhythms. J. Endocrinol. 2005, 184 (1), 153-163.
(19) Crisman, T. S.; Claffey, K. P.; Saouaf, R.; Hanspal, J.; Brecher, P. Measurement of rat heart fatty acid binding protein by ELISA. Tissue distribution, developmental changes and subcellular distribution. J. Mol. Cell. Cardiol. 1987, 19 (5), 423-431.
(20) Levitt, D. G. The pharmacokinetics of the interstitial space in humans. BMC Clin. Pharmacol. 2003, 3 (1), 3 .
(21) Ockner, R. K.; Manning, J.; Kane, J. Fatty acid binding protein. Isolation from rat liver, characterization, and immunochemical quantification. J. Biol. Chem. 1982, 257 (13), 7872-7878.
(22) Maatman, R. G.; van de Westerlo, E. M.; Van Kuppevelt, T.; Veerkamp, J. H. Molecular identification of the liver-and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem. J. 1992, 288 (1), 285-290.
(23) Kimura, H.; Odani, S.; Nishi, S.; Sato, H.; Arakawa, M.; Ono, T. Primary structure and cellular distribution of two fatty acid-binding proteins in adult rat kidneys. J. Biol. Chem. 1991, 266 (9), 5963-5972.
(24) Ellmerer, M.; Schaupp, L.; Brunner, G. A.; Sendlhofer, G.; Wutte, A.; Wach, P.; Pieber, T. R. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am. J. Physiol. Endocrinol. Metab. 2000, 278 (2), E352-E356.
(25) Peters, T. The biosynthesis of rat serum albumin II. Intracellular phenomena in the secretion of newly
formed albumin. J. Biol. Chem. 1962, 237 (4), 1186-1189.
(26) Han, X.; Snow, T. A.; Kemper, R. A.; Jepson, G. W. Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem. Res. Toxicol. 2003, 16 (6), 775-781.
(27) Woodcroft, M. W.; Ellis, D. A.; Rafferty, S. P.; Burns, D. C.; March, R. E.; Stock, N. L.; Trumpour, K. S.; Yee, J.; Munro, K. Experimental characterization of the mechanism of perfluorocarboxylic acids' liver protein bioaccumulation: The key role of the neutral species. Environ. Toxicol. Chem. 2010, 29 (8), 16691677.
(28) Han, X.; Hinderliter, P. M.; Snow, T. A.; Jepson, G. W. Binding of Perfluorooctanoic Acid to Rat Liver - form and Kidney - form a 2 u - Globulins. Drug Chem. Toxicol. 2004, 27 (4), 341-360.
(29) Weaver, Y. M.; Ehresman, D. J.; Butenhoff, J. L.; Hagenbuch, B. Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicol. Sci. 2009, kfp275.
(30) Zhao, W.; Zitzow, J. D.; Ehresman, D. J.; Chang, S.-C.; Butenhoff, J. L.; Forster, J.; Hagenbuch, B. $\mathrm{Na}+$ /taurocholate cotransporting polypeptide and apical sodium-dependent bile acid transporter are involved in the disposition of perfluoroalkyl sulfonates in humans and rats. Toxicol. Sci. 2015, kfv102.
(31) Han, X.; Nabb, D. L.; Russell, M. H.; Kennedy, G. L.; Rickard, R. W. Renal elimination of perfluorocarboxylates (PFCAs). Chem. Res. Toxicol. 2011, 25 (1), 35-46.
(32) Yang, C.-H.; Glover, K. P.; Han, X. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4 , and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol. Sci. 2010, 117 (2), 294-302.
(33) Kemper, R. A. Perfluorooctanoic acid: toxicokinetics in the rat. Project ID: DuPont 2003, 7473.
(34) MacLeod, M.; Fraser, A. J.; Mackay, D. Evaluating and expressing the propagation of uncertainty in chemical fate and bioaccumulation models. Environ. Toxicol. Chem. 2002, 21 (4), 700-709.
(35) Hebert, P. C.; MacManus-Spencer, L. A. Development of a fluorescence model for the binding of medium-to long-chain perfluoroalkyl acids to human serum albumin through a mechanistic evaluation of spectroscopic evidence. Anal. Chem. 2010, 82 (15), 6463-6471.
(36) Yang, Y.; Xu, X.; Georgopoulos, P. G. A Bayesian population PBPK model for multiroute chloroform exposure. J. Expo. Sci. Environ. Epidemiol. 2010, 20 (4), 326-341.
(37) Kim, S.-J.; Heo, S.-H.; Lee, D.-S.; Hwang, I. G.; Lee, Y.-B.; Cho, H.-Y. Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food Chem. Toxicol. 2016, 97, 243-255.
(38) Kudo, N.; Sakai, A.; Mitsumoto, A.; Hibino, Y.; Tsuda, T.; Kawashima, Y. Tissue distribution and hepatic subcellular distribution of perfluorooctanoic acid at low dose are different from those at high dose in rats. Biol. Pharm. Bull. 2007, 30 (8), 1535-1540.


[^0]:    ${ }^{\text {a }}$ All rate constant values shown here are calculated by assuming the body weight of rat is 250 g .
    ${ }^{\mathrm{b}}$ Only kinetics of transporting PFOS was reported ${ }^{30}$. We assume the same kinetics for PFOA.

